PFBT
VRDN icon

Parkside Financial Bank & Trust’s Viridian Therapeutics VRDN Stock Holding History

Parkside Financial Bank & Trust’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37K Hold
70
– – ﹤0.01% 2240
2025
Q4 		$2.18K Hold
70
– – ﹤0.01% 2069
2025
Q3 		$1.51K Hold
70
– – ﹤0.01% 2121
2025
Q2 		$978 Buy
+70
New +$950 ﹤0.01% 2279

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Parkside Financial Bank & Trust's VRDN Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its Viridian Therapeutics (VRDN) position steady in Q1 2026 at 70 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #2240.

Parkside Financial Bank & Trust first reported a position in VRDN in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.18K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Parkside Financial Bank & Trust held 70 shares of Viridian Therapeutics worth $1.37K as of Q1 2026.
  • Parkside Financial Bank & Trust left its Viridian Therapeutics share count unchanged in Q1 2026.
  • Viridian Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2240 holding.
  • Parkside Financial Bank & Trust first reported a position in Viridian Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Parkside Financial Bank & Trust's Viridian Therapeutics position peaked at $2.18K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.